Likewise, serum FSTL3 level was much higher in NAFLD fibrosis high risk patients than in those with NAFLD fibrosis low and intermediate risk, both by NFS and FIB-4 (Fig. 3B, C and Additional file 1: Table S5). The gene discussed is FSTL3; the disease is metabolic dysfunction-associated steatotic liver disease.